MediciNova, Inc. – NASDAQ:MNOV
Founder-led company
MediciNova stock price today
$1.3
-0.76
-37.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
MediciNova stock price monthly change
+43.75%
month
MediciNova stock price quarterly change
+43.75%
quarter
MediciNova stock price yearly change
+42.76%
year
MediciNova key metrics
Market Cap | 102.01M |
Enterprise value | 94.45M |
P/E | -7.67 |
EV/Sales | N/A |
EV/EBITDA | -6.91 |
Price/Sales | N/A |
Price/Book | 1.60 |
PEG ratio | 0.19 |
EPS | -0.17 |
Revenue | N/A |
EBITDA | -1.15B |
Income | -8.40M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMediciNova stock price history
MediciNova stock forecast
MediciNova financial statements
| Jun 2023 | 0 | -2.87M | |
|---|---|---|---|
| Sep 2023 | 1B | -723.10K | -0.07% |
| Dec 2023 | -999.77M | -2.05M | 0.21% |
| Mar 2024 | 0 | -2.75M |
| 2025 | 562.5K | -11.7M | -2080% |
|---|---|---|---|
| 2026 | 79.21M | -12.1M | -15.27% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 68718642 | 3.54M | 5.16% |
|---|---|---|---|
| Sep 2023 | 68136561 | 3.46M | 5.09% |
| Dec 2023 | 66269977 | 3.89M | 5.87% |
| Mar 2024 | 62893917 | 3.06M | 4.87% |
| Jun 2023 | -2.38M | -18.57K | 0 |
|---|---|---|---|
| Sep 2023 | -1.37M | -2.74K | 0 |
| Dec 2023 | -499.06K | 22 | 0 |
| Mar 2024 | -3.86M | 0 | 0 |
MediciNova alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
MediciNova other data
5.13%
-7.53%
of MNOV is owned by hedge funds
23
-17
2.51M
-3.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 0 | 12646 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | NAGAO HIDEKI director | Common Stock | 6,754 | $2.25 | $15,197 | ||
Sale | NAGAO HIDEKI director | Common Stock | 218 | $2.13 | $464 | ||
Sale | NAGAO HIDEKI director | Common Stock | 5,365 | $2.18 | $11,696 | ||
Sale | NAGAO HIDEKI director | Common Stock | 309 | $2.18 | $674 | ||
Option | MATSUDA KAZUKO director, officer: Chief Medica.. | Common Stock | 60,000 | $2.3 | $138,000 | ||
Option | MATSUDA KAZUKO director, officer: Chief Medica.. | Employee Stock Option (Right to Buy) | 60,000 | $2.3 | $138,000 | ||
Option | IWAKI YUICHI director, officer.. | Common Stock | 39,583 | $2.54 | $100,541 | ||
Option | IWAKI YUICHI director, officer.. | Employee Stock option (Right to Buy) | 39,583 | $2.54 | $100,541 | ||
Option | MATSUDA KAZUKO director, officer: Chief Medica.. | Common Stock | 102,804 | $2.5 | $257,010 | ||
Option | MATSUDA KAZUKO director, officer: Chief Medica.. | Employee Stock Option (Right to Buy) | 46,554 | $2.54 | $118,247 |
| Patent |
|---|
Grant Filling date: 10 Jul 2020 Issue date: 20 Sep 2022 |
Application Filling date: 27 Jan 2022 Issue date: 4 Aug 2022 |
Application Filling date: 2 Jul 2021 Issue date: 2 Jun 2022 |
Grant Filling date: 18 Jun 2020 Issue date: 22 Mar 2022 |
Grant Filling date: 18 Oct 2019 Issue date: 26 Oct 2021 |
Application Filling date: 5 Apr 2021 Issue date: 7 Oct 2021 |
Grant Filling date: 1 May 2019 Issue date: 10 Aug 2021 |
Application Filling date: 31 Jul 2020 Issue date: 17 Jun 2021 |
Application Filling date: 21 Sep 2020 Issue date: 25 Mar 2021 |
Grant Filling date: 8 Oct 2019 Issue date: 16 Mar 2021 |
| Insider | Compensation |
|---|---|
| Dr. Yuichi Iwaki (1950) Co-Founder, Pres, Chief Executive Officer & Executive Director | $868,140 |
Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH (1966) Chief Medical Officer & Director | $626,290 |
-
What's the price of MediciNova stock today?
One share of MediciNova stock can currently be purchased for approximately $1.3.
-
When is MediciNova's next earnings date?
Unfortunately, MediciNova's (MNOV) next earnings date is currently unknown.
-
Does MediciNova pay dividends?
No, MediciNova does not pay dividends.
-
How much money does MediciNova make?
MediciNova has a market capitalization of 102.01M.
-
What is MediciNova's stock symbol?
MediciNova, Inc. is traded on the NASDAQ under the ticker symbol "MNOV".
-
What is MediciNova's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MediciNova?
Shares of MediciNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MediciNova's key executives?
MediciNova's management team includes the following people:
- Dr. Yuichi Iwaki Co-Founder, Pres, Chief Executive Officer & Executive Director(age: 75, pay: $868,140)
- Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH Chief Medical Officer & Director(age: 59, pay: $626,290)
-
Is MediciNova founder-led company?
Yes, MediciNova is a company led by its founder Dr. Yuichi Iwaki.
-
How many employees does MediciNova have?
As Jul 2024, MediciNova employs 13 workers.
-
When MediciNova went public?
MediciNova, Inc. is publicly traded company for more then 18 years since IPO on 8 Dec 2006.
-
What is MediciNova's official website?
The official website for MediciNova is medicinova.com.
-
Where are MediciNova's headquarters?
MediciNova is headquartered at 4275 Executive Square, La Jolla, CA.
-
How can i contact MediciNova?
MediciNova's mailing address is 4275 Executive Square, La Jolla, CA and company can be reached via phone at 858 373 1500.
MediciNova company profile:
MediciNova, Inc.
medicinova.comExchange:
NASDAQ
Full time employees:
13
Industry:
Biotechnology
Sector:
Healthcare
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
4275 Executive Square
La Jolla, CA 92037
La Jolla, CA 92037
CIK: 0001226616
ISIN: US58468P2065
CUSIP: 58468P206
